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Background: Targeting cancer cell metabolism is recognized as a promising arena for development of cancer
chemotherapeutics. Moreover, redox metabolism is also systematically altered in tumor cells. Indeed, there is
growing reason to believe that tumor-specific alteration of redox control of metabolism will be central to
understanding and attacking malignancy. We report here that lipoate analog CPI-613 attacks a gate-keeping,
lipoate-using metabolic enzyme, alpha-ketoglutarate dehydrogenase (KGDH), by a redox mechanism selectively
in tumors cells.
Results: CPI-613 inhibited KGDH function strongly and rapidly, selectively in tumor cells. Moreover, CPI-613 induced
a correspondingly rapid, powerful redox signal in tumor cell mitochondria. This signal was associated with redox
modification of KGDH (including extensive enzyme glutathionylation and redox blockage of enzyme lipoate sulfhydryls),
correlating with KGDH inactivation. The source of this tumor-specific mitochondrial redox modulatory signal was not
electron transport complexes (I or III), but was largely or entirely the E3 (dihydrolipoamide dehydrogenase) component
of dehydrogenases, including KGDH. Finally, we demonstrated that KGDH activity was redox regulated (in tumor cells),
as expected if a tumor-specific redox process (auto)regulates KGDH.
Conclusions: Our data demonstrate that lipoate analog CPI-613 attacks redox control of KGDH activity in tumor cells,
perhaps by modulation of an existing lipoate-sensitive allosteric process normally governing tumor cell KGDH activity.
Together with its previously reported, mechanistically distinct (non-redox) effects on the other major, lipoate-using
mitochondrial metabolic enzyme, pyruvate dehydrogenase, CPI-613’s KGDH effects indicate that this agent simultaneously
attacks multiple central, essential components of tumor cell metabolic regulation.
Keywords: Alpha-ketoglutarate dehydrogenase, Cancer metabolism, Chemotherapy, Glutathionylation, Lipoate, Pyruvate
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Reactive oxygen species (ROS) have emerged as potent
signaling molecules with the ability to modulate a num-
ber of cellular signaling processes, owing to their ability
to modify proteins, including via oxidation of specific
cysteine residues [1,2]. ROS have also been found to
directly regulate key enzymes of matter/energy metabol-
ism. The mitochondrial tricarboxylic acid (TCA) cycle* Correspondence: paul.bingham@stonybrook.edu
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reproduction in any medium, provided the orenzyme aconitase has long been known to be inactivated
by ROS through its iron cluster [3]. Moreover, there is
evidence for redox-dependent changes associated with
malignancy-related metabolic alterations in breast can-
cer development [4]. In addition, the glycolytic enzymes
glyceraldehyde 3-phosphate dehydrogenase [5] and the
tumor-specific M2 splice variant of pyruvate kinase [6-8]
have both been shown to be inhibited by the oxidation
of specific cysteine residues, apparently redirecting car-
bon flux through the pentose phosphate pathway and
away from the glycolytic pathway to generate ROS-
detoxifying reducing potential.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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intermediates [9-12] results in increased use of a ‘trun-
cated’ TCA cycle, including diversion of citrate to cyto-
solic export for use in lipid synthesis (Figure 1A). To
replenish TCA cycle intermediates in support of such
anabolic processes, cancer cells rely disproportionately
on glutamine, which enters the cycle as α-ketoglutarate
via the α-ketoglutarate dehydrogenase (KGDH) complex
([13] and Figure 1A).
TCA cycle enzymes are tightly regulated and their ac-
tivities and regulation are often substantially altered in
cancer cells. For example, the pyruvate dehydrogenase
(PDH) regulatory kinases (PDKs 1 to 4), negative regula-
tors of the PDH complex, are up-regulated in many
cancers, apparently to control anabolic flux and to
modulate mitochondrial O2 consumption in the hypoxic
tumor environment [14-17]. Further, results presentedFigure 1 Role of α-ketoglutarate dehydrogenase and its lipoate resid
including the matrix TCA cycle and anabolic diversion of TCA citrate in sup
TCA cycle. Entry of glutamine-derived carbon into the TCA cycle is controll
KGDH complex are illustrated on the right. There are two sources of reduci
(forward reaction) and NADH (reverse reaction). (B) Chemical details of the
pyruvate dehydrogenase are shown. R indicates a succinyl residue in KGDH
of the structures of the two lipoate analogs used in these studies are showherein indicate tumor-specific alteration of KGDH regu-
lation. These generalized alterations of metabolic regula-
tion of cancer cell mitochondrial metabolism represent
potential targets for next-generation chemotherapeutics.
The KGDH and PDH complexes sit at the center of
mitochondrial metabolism, generally controlling the large
majority of carbon flow into the TCA cycle, derived from
glutamine and pyruvate, respectively. PDH and KGDH are
among the small group of enzymes using lipoate as a cata-
lytic cofactor, a role in which lipoate is also known to gen-
erate information addressing tumor-specific alterations in
PDH regulation (references above; reviewed in [18,19]).
Thus, we have explored the use of lipoate analogs as cancer
chemotherapeutic agents.
In contrast to PDH, KGDH is not regulated by phos-
phorylation and has previously been assumed to be con-
trolled primarily by allosteric processes [20]. Evidence isues. (A) On the left are selected details of mitochondrial metabolism,
port of cytosolic lipid biosynthesis. KGDH is an enzyme complex in the
ed by KGDH. Features of the structure and catalytic reactions of the
ng potential for the catalysis of H2O2 production by E3: reduced lipoate
three intermediates in the natural lipoate catalytic cycles of KGDH and
and an acetyl residue in pyruvate dehydrogenase. (C) Selected details
n. KGDH, α-ketoglutarate dehydrogenase; TCA, tricarboxylic acid.
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anisms of KGDH regulation. Applegate and colleagues
[21] report reversible inactivation of KGDH in isolated
mitochondria treated with hydrogen peroxide, with this
inactivation resulting from glutathionylation of the E2
lipoate residues. Intriguingly, the E3 (dihydrolipoamide de-
hydrogenase) subunit of KGDH is also now recognized as a
major source of mitochondrial ROS [22-24], although many
details of this process remain to be defined.
We previously described a member of a novel class of
anti-cancer lipoate derivatives, (CPI-613, Figure 1C) that
specifically induces inactivating phosphorylation of tumor
cell PDH via stimulation of PDKs 1 to 4. This CPI-613-
induced PDH inactivation contributes to the collapse of
mitochondrial function and the activation of multiple
tumor cell death pathways [18]. In addition, we re-
ported very strong CPI-613 tumor growth inhibition in
two human xenograft mouse models, indicating in vivo
efficacy (ibid.). CPI-613 is in early clinical trials, show-
ing a strong safety profile and some early, anecdotal in-
dications of efficacy [25].
We report here the novel effects of CPI-613 on the
second lipoate-containing, mitochondrial enzyme com-
plex, KGDH. CPI-613 induces a large, tumor-specific
burst of mitochondrial ROS, apparently from the E3
subunit of the KGDH complex itself. CPI-613 appears
to hyper-stimulate an endogenous, redox mechanism
for KGDH autoregulation in a tumor-specific fashion.
This ROS signal inhibits KGDH activity with associated
glutathionylation of enzyme sulfhydryls, and redox modifi-
cation of the endogenous lipoate residues of the KGDH E2
subunit. Combined with its mechanistically distinct effects
on PDH, this CPI-613-induced inhibition of KGDH con-
tributes to powerful tumor-specific inhibition of mitochon-
drial metabolism. Thus, this single drug simultaneously and
independently attacks two central, essential metabolic
multi-enzyme complexes, including KGDH, which may
occupy a previously unexplored interface between tumor-
specific redox regulation and matter/energy metabolism.
Methods
Cell culture
The human non-small cell lung carcinoma cell line NCI-
H460 and pancreatic carcinoma cell line BxPC-3 were
purchased from the American Type Culture Collection
(Manassas, VA, USA) and cultured in Roswell Park Me-
morial Institute (RPMI)-1640 medium supplemented with
10% fetal bovine serum, 100 units/ml penicillin and 100 μg/
ml streptomycin (Life Technologies, Carlsbad, CA, USA)
unless otherwise indicated.
Normal human bronchial/tracheal epithelial (HBT)
cells were purchased from Lifeline Cell Technology
(Walkersville, MD, USA) and were propagated according
to the supplier’s instructions in media developed by andobtained from the supplier. Experiments reported used
normal cells at passages six to ten.
H460 cells lacking mitochondrial DNA (ρ°) were de-
rived as described previously [26].
Chemicals
Highly purified CPI-613 and CPI-157 were synthesized
from D,L lipoate as described previously [18]. N-
acetylcysteine (NAC), auranofin, resazurin, diaphorase,
glutaredoxin-1, reduced glutathione, Triton X-100, digi-
tonin, lauryl maltoside, dithiothreitol (DTT), NAD+,
ADP, thiamine pyrophosphate, coenzyme-A (CoA), and
N-ethylmaleimide (NEM) were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Biotin-HDPD and gel fil-
tration columns (PD10) were from Thermo Scientific
(Waltham, MA, USA). 2',7'-dichlorodihydrofluorescein dia-
cetate (DCF), dihydroethidium (DHE), and Amplex Red
were from Life Technologies. Antibodies to Prx1, Prx3 and
reduced lipoate were purchased from AbCam (Cambridge,
MA, USA). Antibodies against dihydrolipoamide dehydro-
genase (E3) were from Rockland Immunochemicals
(Gilbertsville, PA, USA) and KGDH dihydrolipoamide
succinyltransferase (E2) antibodies were from Cell Sig-
naling (Danvers, MA, USA).
ATP assay
Total cellular ATP levels were measured using CellTiter-
Glo luminescence assay (Promega, Madison, WI, USA)
according to manufacturer’s directions.
Assessment of mitochondrial ATP production from
different carbon sources
H460 cells were seeded at 10,000 cells per well in black,
clear bottom, 96-well plates in RPMI (11 mM glucose,
2 mM glutamine) medium and grown overnight. The
medium was then changed to RPMI without glucose and
containing 10 mM pyruvate and 2 mM glutamine alone
or together with 0.1 mM water soluble oleic acid
(Sigma-Aldrich). After 24 hours, the medium was re-
placed with fresh RPMI without glucose and containing
either 10 mM pyruvate and 2 mM glutamine or 0.1 mM
oleic acid and 0.5 mM aspartate (matched to overnight
adaptation) and containing CPI-613 (240 μM) in the
treated samples or solvent alone in the controls for
2 hours before ATP level measurements.
Cells in these final media without drug treatment re-
tain stable and robust ATP production (exclusively mito-
chondrial) for more than 6 hours, with pyruvate plus
glutamine and oleic acid generating comparable ATP
outputs.
Small interfering RNAs
Small interfering RNA (siRNA) duplexes against dihy-
drolipoamide dehydrogenase (E3) were purchased from
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5’-CCUGUGAAGAUAUAGCUA, 5’-CAGACUCUAGC
UAUAUCU. siRNA duplexes were transfected into NCI-
H460 cells using Lipofectamine 2000 (Life Technologies)
as per manufacturer’s instructions.
CO2 release through carbon source oxidation
Oxidative release of carbons as carbon dioxide from glu-
tamate was assayed by filter capture as described in [4]
with minor modifications. We seeded 48-well plates with
100,000 cells per well in 0.5 ml of medium. After 18 to
25 hours, the medium was replaced with fresh medium
containing drug solvent (dimethyl sulfoxide) alone or
with CPI-613 for time intervals and drug concentrations
as indicated. For the last 30 minutes of incubation,
0.3 μCi of radiolabeled substrate was added. At termination,
75 μl of 3 M perchloric acid was added to each well and
wells were immediately covered with phenylethylamine-
saturated 3 mm discs to capture released CO2. After
24 hours, discs were transferred into scintillation vials con-
taining 1 ml of Biosafe-II scintillation cocktail (Research
Products, International, Mount Prospect, IL) and counted.
Quantitation of intracellular reactive oxygen species levels
H460 cells were plated in 35 mm tissue culture dishes at
a density of approximately 300,000 cells and grown over-
night. After 16 to 20 hours, drug or vehicle control was
added for specified times. For the final 15 minutes of
drug treatment, 5 μM DCF or dihydroethidium (DHE)
was added. Cells were then detached via trypsinization
and collected for fluorescence-activated cell sorting
(FACS) analysis on a FACScalibur flow cytometer (BD,
Franklin Lakes, NJ, USA) using CellQuest Pro software.
Steady state metabolite levels determination
In brief, samples were extracted and split into equal
parts for analysis on the gas chromatography-mass spec-
trometry and liquid chromatography-tandem mass spec-
trometry platforms [27]. Proprietary software was used
to match ions to an in-house library of standards for
metabolite identification and for metabolite quantitation
by peak area integration [28].
Extracts were prepared according to Metabolon’s
(Durham, NC, USA) standard methanol-based extrac-
tion protocol [27]. Samples were analyzed on a Thermo-
Finnigan Trace DSQ fast-scanning single-quadrupole
mass spectrometer (Waltham, MA) using electron im-
pact ionization. (For additional technical details on
cell preparation, techniques and statistical analysis, see
Additional file 1).
Western blot analysis
For western blot analysis, 2X lithium dodecyl sulfate
(LDS) loading buffer (500 mM Tris (pH 8.5), 4% LDS,20% glycerol, 1 mM EDTA, 0.44 mM SERVA Blue G250,
0.35 mM Phenol Red, plus 100 mM DTT unless other-
wise noted) was added to samples followed by heating at
70°C for 10 minutes. Proteins were separated via
SDS-PAGE then transferred to polyvinylidene difluoride
membranes and detected via chemiluminescence using
the WesternBreeze detection kit (Life Technologies).
Detection of glutathionylated proteins
Glutathionylated proteins were detected as described
previously with modifications [21]. Briefly, cells were
treated for 3 hours with CPI-613, washed with PBS then
treated with ice-cold N-buffer (40 mM HEPES (pH 7.4),
50 mM NaCl, 1 mM EGTA, 1 mM EDTA, plus Pierce
protease inhibitor cocktail) containing 100 mM NEM
for 5 minutes to alkylate free sulfhydryls. Mitochondria
were then purified as described previously [29] and perme-
abilized with 0.05% Triton X-100. Unreacted NEM was
scavenged with 1 mM NAC followed by treatment with 2.0
units/ml glutaredoxin and 1.4 mM reduced glutathione to
deglutathionylate protein cysteines. Free cysteines were
then labeled with 1.6 mM biotin-HPDP for 5 minutes
followed by addition of 2 mM NAC to scavenge unreacted
biotin-HPDP. Biotin-HPDP-NAC was removed by gel
filtration and streptavidin-conjugated Dynabeads (Life
Technologies) were used to capture biotinylated (glu-
tathionylated) proteins as per manufacturer’s instruc-
tions. Beads were then mixed with 2X LDS loading
buffer containing 100 mM DTT to release captured
proteins followed by western blot analysis.
Lipoate protection assay
Cells were washed twice with ice-cold PBS before expos-
ure to ice-cold N-buffer containing 10 mM NEM to
block non-derivatized lipoates. Following a 5 minute in-
cubation on ice, CHAPS was added at a final concentra-
tion of 1% to lyse cells. Lysates were transferred to
1.5 ml microfuge tubes and incubated on ice for an add-
itional 5 minutes with occasional vortexing followed by
centrifugation at 15,000x g for 10 minutes to pellet in-
soluble material. Supernatants were then mixed 1:1 with
2X LDS loading buffer containing DTT at a final con-
centration of 100 mM to reverse oxidative modifications
of lipoate (including removal of glutathione residues)
and analyzed via SDS-PAGE and western blot with anti-
body against non-derivatized lipoate.
Hydrogen peroxide production assay
Hydrogen peroxide production by purified porcine KGDH
(Sigma-Aldrich) in vitro was measured using the Amplex
Red hydrogen peroxide assay kit (Life Technologies) ac-
cording to manufacturer’s instructions and as described
in [22].
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Peroxiredoxin oxidation status was assayed as described
previously [30] with minor modifications. Following
treatment, cells were washed twice with ice-cold PBS then
incubated with ice-cold N-buffer containing 100 mM NEM
for 10 minutes on ice. CHAPS was added at a final concen-
tration of 1% and incubated on ice for a further 10 minutes
with shaking. Samples were centrifuged for 10 minutes at
15,000x g to pellet insoluble material. Supernatant was
combined with 2X loading buffer (without DTT) and pro-
teins were resolved via SDS-PAGE under oxidizing condi-
tions and probed via western blot.
In vitro analysis of α-ketoglutarate dehydrogenase activity
Cells grown on solid substrate in the same 48-well plate
format as employed for flux analysis (either treated or
untreated with CPI-613) were lysed for 2 minutes at
room temperature with 0.03% digitonin in PBS to
selectively disrupt plasma membranes, releasing cyto-
solic nicotinamide coenzymes and carbon sources. This
initial lysis solution was replaced with mitochondrial
lysis butter (0.5% lauryl maltoside, 50 mM Tris (pH 7.4)
and 1 mM MgCl2) for two minutes. Twelve-minute reac-
tions were initiated by adding a 10X buffer to the mito-
chondrial lysates, producing the following final component
concentrations: 0.6 mM or 0 mM α-ketoglutarate; 50 μM
CoA; 225 μM thiamine pyrophosphate; 250 μM NAD+;
50 μM ADP; 15 μM glutathione; 15 μM resazurin; 0.5
units/ml diaphorase. NAD+ reduction was assayed by resa-
zurin reduction as above. Reaction rates were linear over
this reaction time.
To further investigate the role of redox modification of
KGDH in drug-induced inhibition of KGDH, 10 mM DTT
was added to both lysis buffers in duplicate reactions.
Statistical analysis
Except where otherwise noted, Student’s t-test was used
for data analysis. P <0.05 was considered significant. All
error bars are standard error of the mean (SEM).
Results
CPI-613 induces a strong mitochondrial burst of reactive
oxygen species
To further explore the metabolic and cell death effects
produced by CPI-613 treatment, we initially investigated
production of ROS, which have emerged as regulatory
effectors of both phenomena [31]. Using the ROS-
sensitive, cell permeant dye DCF, we observed a robust
dose-dependent increase in intracellular ROS levels in
H460 human lung carcinoma cells treated with CPI-613
(Figure 2A). Moreover, the amount of ROS produced in
response to CPI-613 was several-fold higher than that
produced by traditional mitochondrial ROS inducerssuch as rotenone and thenoyltrifluoroacetone delivered
under conventional conditions (Figure 2B).
Mitochondria are a major source of intracellular ROS
[31]. To test whether mitochondria were the source of
CPI-613-generated ROS, we compared the redox status
of the mitochondrial and cytosolic cellular compart-
ments by monitoring oxidation of compartment-specific
isoforms of the peroxiredoxin antioxidant proteins [32]
in response to acute drug exposure. Initial treatment of
H460 cells with CPI-613 caused an increase in the oxi-
dized dimer of the mitochondrial Prx3 isoform with no
corresponding increase for the cytosolic Prx1 isoform
(Figure 2C). The increase in Prx3 dimerization was dose
dependent (Figure 2D) and inhibited by the antioxidant
NAC (Figure 2D). Furthermore, NAC also significantly
protected cells from drug-induced death as assayed by
whole cell ATP levels and cell morphology after 16 hours
of drug treatment (Figure 2E). Taken together, these data
indicate that mitochondria are the source of CPI-613-
induced ROS and implicate this ROS as contributing to
CPI-613-induced cell death.
Electron transport chain complexes I and III are not
the source of CPI-613-induced mitochondrial reactive
oxygen species
Mitochondrial ROS are traditionally associated with per-
turbation of electron flow through complexes I and III
of the electron transport chain (ETC). To investigate the
involvement of the ETC in CPI-613-induced ROS and
metabolic effects, we generated ρ°-H460 cells that lacked
several essential mitochondrial-encoded components of
the ETC, and thus generate neither mitochondrial ATP nor
ETC-associated ROS from complexes I or III [33,34]. We
validated the ρ°-H460 cells by examining the levels of mito-
chondrial DNA (mtDNA)-encoded proteins. Figure 3A
shows no detectable levels of the mtDNA-encoded protein
cytochrome c oxidase subunit I in these ρ° cells, whereas
the nuclear-encoded proteins actin and dihydrolipoyl de-
hydrogenase (E3) were at comparable levels to parental (ρ+)
H460 cells, as expected. Further, these cells could no longer
produce ROS in response to the ETC complex III inhibitor
antimycin-A as assessed by DHE oxidation (Figure 3B),
further confirming their ρ° status. Finally, ρ° status also sub-
stantially attenuated ROS production by the ETC complex
I inhibitor rotenone without a corresponding effect on CPI-
613-induced ROS by this same assay (Additional file 2).
By contrast, ρ°–H460 cells continued to show a large
increase in ROS levels when treated with CPI-613. The
magnitude of this increase is similar to that seen in ρ+-
H460 cells (Figure 3B). Additionally, ρ° cells treated with
CPI-613 displayed increased oxidized mitochondrial
Prx3 levels (Figure 3C) and had similar sensitivity to
drug-induced cell death as the parental (ρ+) H460 cells
(results not shown). These results indicate little or no
Figure 2 CPI-613 induces a strong mitochondrial burst of reactive oxygen species implicated in cell death. (A, B) Intracellular ROS levels
were assayed using the hydrogen peroxide-sensitive dye DCF followed by FACS quantification. CPI-613 treatment causes a dose-dependent increase in
whole cell DCF signal several-fold higher (A) than that caused by classical ROS inducing agents such as rotenone and TTFA at their conventional doses (B).
Results are representative of three experiments. (***P <0.0005 compared to vehicle control; Student’s t test; n = 3). (C) Upper panel: Levels of dimerization
(oxidization) of the cytosolic (Prx1) and mitochondrial (Prx3) isoforms of peroxiredoxin induced by CPI-613 or the mitochondrial inhibitor of ROS
detoxification, auranofin, as a control were assayed by western blot (under oxidizing gel conditions). Lower panel: parallel samples were treated
with 100 mM DTT and run under reducing gel conditions (converting all peroxiredoxin to the reduced monomer form and serving as a loading
control). (D) CPI-613-induced Prx3 dimerization is dose dependent (left) and inhibited by co-treatment of cells with the antioxidant NAC (right). (E) NAC
protects from cell death induced by CPI-613 as assayed by long-term ATP levels (16 hours) and cell morphology. Error bars represent SEM. DCF,
2',7'-dichlorodihydrofluorescein diacetate; DMSO, dimethyl sulfoxide; DTT, dithiothreitol; NAC, N-acetylcysteine; TTFA, thenoyltrifluoroacetone.
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induced ROS production and cell death. Finally, NAC
also protected ρ°-H460 cells from drug-induced cell death
(compare Figures 2E and 3D), indicating that ROS-
dependent effects originating from some mitochondrial
source other than complexes I or III contribute to CPI-
613-induced cell death.
E3 is a major source of the CPI-613 stimulated reactive
oxygen species signal
The dihydrolipoyl dehydrogenase (E3 subunit) of KGDH
has been identified as a major, non-ETC generator ofmitochondrial ROS [22,23]. We used the hydrogen
peroxide-detecting dye Amplex Red to examine the ef-
fects of CPI-613 on hydrogen peroxide production by
purified porcine heart KGDH. CPI-613 treatment re-
sulted in an increase in hydrogen peroxide production,
suggesting that KGDH might be a source of the in vivo
CPI-613 mitochondrial ROS signal (Figure 4A). Note
that changes in fluorescence shown in Figure 4A are
not the result of direct drug effects on the Amplex Red
assay system, as demonstrated by controls in which
KGDH is absent (Additional file 3). Furthermore, the
related lipoate analog, CPI-157 (Figure 1C), which does
Figure 3 CPI-613-induced mitochondrial reactive oxygen species originate from a non-electron transport chain source. (A) ρ° cells
lacking mtDNA-encoded components of the ETC were generated from H460 (ρ+) as described previously [26] and validated by western blot,
demonstrating the absence of the mtDNA-encoded protein cytochrome c oxidase subunit 1 (COX1) but containing nuclear-encoded mitochondrial
protein dihydrolipoamide dehydrogenase (E3). The nuclear-encoded cytosolic actin protein served as a loading control. (B) ROS levels were quantified
following treatment with 240 μM CPI-613 or 4 μM antimycin-A using the superoxide-detecting dye DHE followed by FACS analysis. CPI-613 induced
comparable amounts of ROS in ρ° and ρ+ cells whereas the complex III ROS inducer antimycin-A failed to increase DHE fluorescence in ρ° cells. Results are
representative of three experiments. (C) ρ° H460 cells were assayed for oxidation of the mitochondrial Prx3 protein comparably to ρ+ in Figure 2C. These
ρ° cells produced high levels of mitochondrial ROS by this assay despite lacking key ETC components. (D) The antioxidant NAC protects from CPI-613-
induced cell death in ρ° cells as assayed by whole cell ATP levels after 20 hours of drug treatment. Error bars represent SEM. DHE, dihydroethidium; DMSO,
dimethyl sulfoxide; mtDNA, mitochondrial DNA; NAC, N-acetylcysteine.
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kills tumor cells poorly (Figure 4C), failed to increase
in vitro KGDH ROS production. Collectively, these ob-
servations corroborate KGDH E3 as a possible in vivo
source of CPI-613-induced ROS.
To test this hypothesis directly, we used siRNA to knock-
down E3 protein (Figure 4D). Following knockdown of E3
levels to <10% of endogenous levels, we observed a signifi-
cant decrease in mitochondrial ROS (as assayed by Prx3
dimerization) following drug treatment (Figure 4D, quanti-
fied in 4E). This observation strongly supports the hypoth-
esis that the E3 of the mitochondrial dehydrogenase
complexes is an important source of CPI-613-inducedROS. Finally, E3 knockdown significantly protected from
CPI-613-induced cell death (Figure 4F) after 16 hours of
drug treatment.
The partial protection from cell death in this experiment
coupled with our earlier observation of a similar, partial
protection when the PDKs are knocked down [18] collect-
ively indicate that CPI-613 effects on both PDH and KGDH
contribute to drug-induced cell death in H460 cells. More
specifically, each of these protection effects is highly repro-
ducible and statistically significant; however, longer treat-
ment times or higher drug doses overcome protection, as
expected if targeting of KGHD and PDH can each make a
partial contribution to CPI-613-induced cell death.
Figure 4 Analysis of generation and effects of hydrogen peroxide by α-ketoglutarate dehydrogenase in vivo and in vitro. (A) In vitro
generation of H2O2 by KGDH was quantified using Amplex Red oxidation. Co-incubation of KGDH with CPI-613 increased H2O2 generation by
KGDH in vitro. CPI-157, a lipoate analog lacking in vivo anti-cancer activity, was used as a negative control (see panels B and C). CPI-157 failed to
increase in vitro KGDH ROS production. Data are representative of three independent experiments. (**P <0.005 compared to control, ns = not
significant compared to control; Student’s t-test; n = 3). (B) CPI-157 stimulates mitochondrial H2O2 generation poorly in treated cells as assessed
by Prx3 oxidation. (C) CPI-157 is an inactive lipoate analog as assessed by its limited capacity to kill tumor cells. (D) Following siRNA-mediated
knockdown of the E3 (dihydrolipoamide dehydrogenase) subunit, H460 cells were exposed to 240 μM CPI-613 for 3 hours and Prx3 oxidation was
assayed (left). Assessment of E3 protein levels in siRNA treated cells demonstrates efficient knockdown (right). (E) Quantification of dimer:monomer
ratios in panel D using NIH Image-J software **P <0.005 (Student’s t test; n = 3); ***P <0.0005 (Student’s t test; n = 3); ns = not significant. (F) H460 cells
treated for 16 hours with 240 μM CPI-613 following siRNA knockdown of E3 were assayed for ATP content using Cell-TiterGlo Kit (Promega). ATP loss
under these conditions is diagnostic of cell death [18]. Data are expressed as percent of DMSO control. **P <0.005 (Student’s t test; n = 3). All results
representative of at least three experiments. Error bars represent SEM. DMSO, dimethyl sulfoxide; DTT, dithiothreitol.
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a redox-dependent manner by CPI-613 treatment
ROS have been shown to regulate a number of cellular
metabolic enzymes [3,5,8]. Moreover, several studies in-
dicate that KGDH may be redox regulated (reviewed in
[35,36]). These observations suggest the hypothesis thatKGDH may not only be a source of the CPI-613 induced
ROS signal, but also a target of that signal.
To investigate the effects of CPI-613 on KGDH activity,
we examined carbon flux through KGDH by monitor-
ing CO2 release from cells pulse-labeled with 1-
14C-
glutamate. Glutamate is converted to α-ketoglutarate
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through oxidative decarboxylation by KGDH, resulting
in the release of the 1-carbon as CO2. Treatment of
cells with CPI-613 results in a large reduction in radi-
olabeled CO2 release after a 1-
14C-glutamate pulse in
both H460 lung carcinoma (Figure 5A) and BxPC-3
(Figure 5B) pancreatic carcinoma cells, indicating that
CPI-613 inhibits KGDH activity. Note that drug-
induced cell death makes a negligible contribution to
the reduction in KGDH activity at these short treat-
ment times (Figure 5A,B).
To further corroborate inhibition of KGDH activity by
CPI-613, we carried out a steady-state metabolomics
analysis in BxPC-3 cells in collaboration with Metabo-
lon, Inc. Treatment of BxPC-3 cells with CPI-613 re-
sulted in reduction of the levels of succinate, fumarate
and malate, TCA cycle intermediates downstream of
KGDH, as expected if KGDH is inhibited by drug treat-
ment (Figure 5C,D). Though levels of substrates α-
ketoglutarate and pyruvate were too low to measure in
these experiments, glutamine (a proxy for KGDH sub-
strate) showed scaled intensity levels 25% higher in
treated cells, corroborating KGDH inhibition. As a more
general control for the decrease in TCA cycle intermedi-
ates, we observed the expected elevation in diverse me-
tabolites whose catabolism depends on the TCA cycle
(for example, 33% elevation for alanine and 28% for as-
partate). Note that citrate levels were also reduced, con-
sistent with the known inhibition of PDH activity by
CPI-613 [18]. This reduction in citrate levels is unlikely
to be the cause of reduced succinate, fumarate and mal-
ate levels in view of the anaplerotic input from glutam-
ine through KGDH.
We previously demonstrated significant tumor cell se-
lectivity of CPI-613 effects, showing that drug inhibition
of PDH by over-stimulation of regulatory phosphoryl-
ation was highly selective for tumor cells, correlating
with significant selectivity for cell-death induction in
tumor cells (see Figure 4B in [18]). Here, we add import-
ant new pieces of evidence for CPI-613 tumor cell se-
lectivity. Specifically, robust Prx3 oxidation and KGDH
flux inhibition by CPI-613 were not seen in the normal,
primary human bronchial epithelial cell line HBT (a
non-malignant control for H460 lung tumor cells) in re-
sponse to CPI-613 (Figure 5E,F).
To assess the possibility that these results reflect a
broad loss of mitochondrial function, rather than spe-
cific inhibition of KGDH, we investigated acute effects
of CPI-613 on energy production by fatty acid oxidation.
This process yields substantial mitochondrial ATP inde-
pendently of the TCA cycle, whose function is compro-
mised by KGDH and PDH inactivation. Specifically,
initial mitochondrial beta oxidation of fatty acids delivers
reducing equivalents directly to the electron transportsystem. The resulting acetate units (acetyl-CoA) are
excreted as citrate allowing cyclic regeneration of free
CoA through the citrate synthase reaction. The citrate
synthase reaction is provided with its other necessary
substrate, oxaloacetate, through transamination of media-
provided aspartate.
To examine the status of these functions, we exploited
our previous demonstration that mitochondrial ATP
synthesis can be examined directly when cells are pro-
vided with exclusively mitochondrial carbon sources (no
glucose) [18]. As expected, mitochondrial ATP synthesis
in H460 cells sustained by TCA cycle-dependent sub-
strates (pyruvate and glutamine) was rapidly and cata-
strophically inhibited by CPI-613 treatment (Figure 6D).
By contrast, when these cells were provided with a fatty
acid (oleic acid) as the sole major carbon source, acute
drug treatment consistently produces little or no effect
on ATP synthesis (Figure 6D).
This result demonstrates that substantial segments of
mitochondrial energy metabolism external to the TCA
cycle remain functional (including the beta-oxidation
machinery, the electron transport system, and the ATP
synthase), consistent with CPI-613 effects being re-
stricted to specific targets, including KGDH.
CPI-613 induces reactive oxygen species-mediated inacti-
vation and glutathionylation of α-ketoglutarate
dehydrogenase
The dihydrolipoamide succinyltransferase (E2) subunit of
KGDH contains sulfurs with the characteristics expected of
redox-sensitive targets, including those of the enzyme’s
lipoates (Figure 1). When exposed to ROS, these sulfurs are
vulnerable to oxidative modifications, including those cul-
minating in glutathionylation. Glutathionylation of lipoate
sulfhydryls is associated with enzymatic inhibition in re-
sponse to ROS exposure [24]. To test whether ROS-
induced glutathionylation occurred in response to
CPI-613 treatment, we used a modification of the
biotin-switch assay to enrich for glutathionylated pro-
teins [21]. Following CPI-613 treatment we observed a
large increase in glutathionylation levels of the E2 sub-
unit of KGDH (Figure 6A). Notably, this increase in
KGDH E2 glutathionylation was prevented by NAC
treatment, providing further evidence for the direct in-
volvement of ROS in CPI-613 modification of KGDH
activity.
In addition to the sulfurs of lipoate, the E2 subunit
contains multiple cysteine residues that could also be
susceptible to glutathionylation. To test whether the
lipoate residues of KGDH might be targets of drug-
induced redox modification, we took advantage of anti-
bodies recognizing native lipoate but not chemically
modified lipoate. Glutathionylation and/or other redox
modifications protect lipoate sulfurs from chemical
Figure 5 (See legend on next page.)
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Figure 5 CPI-613 inhibits α-ketoglutarate dehydrogenase activity selectively in tumor cells. (A, B) Flux through KGDH was assayed in H460 (A)
and Bx-PC3 (B) tumor cells using pulse delivery of 1-14C-labeled glutamate, whose labeled carbon is released as CO2 by KGDH. Each flux panel is coupled
on the right with a parallel experiment demonstrating that commitment to and execution of cell death (measured by ATP levels, before or after 3 hours of
recovery from drug treatment) occurs well after times used for flux analysis. (C) Steady-state metabolite analysis of BxPC-3 tumor cells after 2-hour treat-
ment with 240 μM CPI-613 (shaded boxes) compared to mock-treated samples (open boxes) shows decreases inTCA cycle intermediates citrate, succinate,
fumarate and malate and increases in anaplerotic inputs alanine, aspartate and glutamine. (D) Diagram of the TCA cycle, its two main carbon entry points,
and anaplerotic transaminations supporting alanine and aspartate catabolism. (E, F) Normal HBT cells show no increase in Prx3 oxidation (E) and only a
slight, transient inhibition of KGDH flux (F) under conditions producing robust effects in lung cancer cells. Vehicle control in panel F refers to the tumor
cells; the HBT vehicle control behaved similarly. All results are representative of at least three experiments or (panel C) data point collections. Error bars
represent SEM except for panel C in which they represent 95% confidence limits. Box plots (panel C) are used to convey the spread of the data with the
middle 50 % of the data represented by boxes and whiskers reporting the range of the data. The solid bar across the box represents the median value of
those measured while the + is the mean. Any outliers are shown as dots outside the whiskers of the plot. DTT, dithiothreitol; HBT cells, primary human
bronchial/tracheal epithelial cells; KGDH, α-ketoglutarate dehydrogenase.
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treatment resulted in significantly fewer alkylated lipoate
residues following NEM exposure (Figure 6B). This result
demonstrates that KGDH lipoate residues acquire revers-
ible, redox-sensitive modifications (consisting of glutathio-
nylation and/or other derivatizations) expected to block
KGDH E2 activity as a result of CPI-613 treatment.
To confirm that CPI-613 directly inhibits KGDH, we
examined enzyme activity in lysates from treated cells.
While the labile status of redox protein modifications is
sufficiently high that we do not expect enzymes in ly-
sates to fully recapitulate in vivo effects, we nonetheless
explored whether we could retain measureable KGDH
modification in vitro. As expected, CPI-613 treatment of
H460 cells produced a significant, reproducible reduc-
tion in KGDH activity in the resulting lysates (Figure 6C).
Moreover, this drug-induced KGDH inhibition was elim-
inated by treatment of the lysates with the reducing
agent, DTT (Figure 6C). This result confirms that CPI-
613 effects include direct inhibition of KGDH activity in
a redox-dependent fashion.
The small super-induction of KGDH activity by DTT
treatment in this study is reproducible and suggestive.
We explore its significance in the more robust in vivo
environment in the following section.
Evidence for redox autoregulation of α-ketoglutarate de-
hydrogenase activity
The results above indicate that KGDH is both a source
and a target of CPI-613-induced ROS. This introduces
the possibility that KGDH is autoregulated in a redox-
dependent fashion (at least in tumor cells) and that CPI-
613 perturbs this process. To test this hypothesis, we
examined the effect of NAC on carbon flux through
KGDH, independent of drug treatment, utilizing the
1-14C-glutamate oxidation assay (as above). Figure 6E
shows that flux through KGDH was significantly ele-
vated by the presence of NAC in non-drug-treated H460
tumor cells. Furthermore, NAC treatment substantially
protected against KGDH flux inhibition induced by CPI-613. Note especially that the magnitude of NAC protec-
tion from CPI-613 effects was substantially greater than
the NAC effects on flux through KGDH in untreated
cells. These results indicate that NAC protects cells from
the action of CPI-613 on KGDH activity, in addition to
its effects on KGDH regulation in the absence of drug.
Collectively, these results strongly suggest that ROS
play a significant role in the regulation of KGDH in
tumor cells and that CPI-613 interacts with this regula-
tion in a manner that results in strong additional redox
inhibition of KGDH activity (Figure 6F).
Discussion
We report new insights into the anti-cancer mechanism
of action of CPI-613, a member of a novel lipoate analog
agent class. Our definition of a new drug target here, to-
gether with our earlier work [18], indicate that CPI-613
simultaneously attacks two pivotal tumor mitochondrial
metabolic enzymes, each through a distinct proximate
mechanism. Moreover, collectively, these two CPI-613
targets, PDH and KGDH, control the majority of the
carbon flux through the TCA cycle in most tumor cells. Fi-
nally, the KGDH and PDH regulatory targets of these
agents appear to behave substantially differently in tumor
cells than in normal cells, conferring significant tumor se-
lectivity on CPI-613.
ROS are intimately associated with mitochondrial func-
tion and dysfunction. Moreover, redox signaling is exten-
sively altered in tumor cells (reviewed in [36-39]). We
observed a large burst of ROS upon CPI-613 treatment of
tumor cells localized to mitochondria. The primary source
of this mitochondrial ROS burst was not complex I or III of
the ETC, as ρ° cells lacking the capacity for ROS generation
from these sources displayed a comparable ROS surge.
Rather, CPI-613-induced ROS generation was largely or en-
tirely dependent upon the dihydrolipoamide dehydrogenase
(E3) component of mitochondrial dehydrogenase com-
plexes, including KGDH.
Consistent with this drug-induced E3 ROS generation
playing a role in cell death, E3 RNAi knockdown
Figure 6 CPI-613 induces reactive oxygen species-mediated glutathionylation and inhibition of tumor cell α-ketoglutarate dehydrogenase. (A)
KGDH E2 enriched in CPI-613-treated cells following capture of glutathionylated proteins using biotin-switch (text). KGDH glutathionylation suppressed by
co-treatment with 250 μM NAC. (B) Cells were treated with 240 μM CPI-613 then exposed to 100 mM NEM followed by 100 mM DTT, chemically reversing
redox modifications. Western blot analysis of native KGDH lipoate indicates increased levels of NEM-protected residues in CPI-613-treated samples. Thus,
KGDH lipoate sulfurs are a target of drug-induced redox modification. (C) α-ketoglutarate produces robust in vitro NAD+ reduction and this process is
significantly inhibited in CPI-613-treated cells. This inhibition is relieved by 10 mM DTT treatment of the lysates. Thus, KGDH from CPI-613-treated cells is
inhibited by redox modification. (D) CPI-613 (2 hours at 240 μM) selectively inhibits mitochondrial ATP production driven by PDH and KGDH substrates,
pyruvate and glutamine, but not driven by fatty acid oxidation. (E) 500 μM NAC increases carbon flux through KGDH, suggesting a role for H2O2 in KGDH
regulation in H460 tumor cells. NAC treatment strongly reverses the inhibition of KGDH activity by CPI-613. The magnitude of this effect (4.7-fold) is greater
than the increase in carbon flux in untreated cells (2.3-fold), indicating that NAC acts to reverse CPI-613 inhibition of KGDH activity in addition to its effects
on KGDH regulation in absence of drug. (F) Proposed model of mechanism of action of CPI-613 on KGDH. CPI-613 may ‘misinform’ existing tumor cell
KGDH redox autoregulation (shaded block arrow), increasing this ROS signal generated by the E3 subunit (including from the reverse reaction, NADH
oxidation), resulting in E2-subinit redox modification and KGDH inhibition. All results are representative of at least three independent experiments. Error bars
represent SEM. DMSO, dimethyl sulfoxide; DTT, dithiothreitol; KGDH, α-ketoglutarate dehydrogenase; NAC, N-acetylcysteine; NEM, N-ethylmaleimide.
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and cell death following CPI-613 treatment. Concomi-
tant with KGDH ROS generation, we observed a marked
decrease in KGDH enzymatic activity that was prevented
by co-treatment with the antioxidant NAC, indicating
ROS-induced inhibition of KGDH. We also show that
redox modification of KGDH correlated with inhibition
of this enzyme’s activity, both in cultured cells and in
cell lysates from treated cells. KGDH was strongly glu-
tathionylated in response to CPI-613 treatment and
KGDH lipoates were modified in a redox-sensitivemanner. Glutathionylation of these lipoate sulfhydryls
has been previously demonstrated in response to direct
treatment of respiring mitochondria with hydrogen
peroxide and these modifications block KGDH func-
tion as expected [21]. The redox modifications of
KGDH lipoates we observed may or may not include
glutathionylation; however, any redox modification of
these lipoates is expected to block KGDH E2 function.
The mechanism of KGDH ROS generation is not com-
pletely understood. However, the E3 subunit is known to
act in both the physiological (forward, reduction of NAD+
Stuart et al. Cancer & Metabolism 2014, 2:4 Page 13 of 15
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lipoamide to dihydrolipoamide) directions. The work of
Ambrus and collaborators indicates that, under condi-
tions where normal substrates such as NAD+ are present
at unusually low levels, the FAD domain of E3 will, in-
stead, transfer electrons to molecular oxygen. This gen-
erates superoxide, which is, in turn, rapidly dismutated
to hydrogen peroxide spontaneously and through mito-
chondrial superoxide dismutase activity [40]. Moreover,
reducing potential (reduced lipoamide or NADH) from
either the forward or reverse reactions, respectively, can
be used by E3 to generate superoxide or hydrogen perox-
ide [35]. Collectively, these results indicate that both
the oxidation and reduction status of KGDH lipoates
and the E3 generation of hydrogen peroxide are sensitive
reflections of the energy status of the mitochondrial
matrix.
In view of these observations, our data strongly sug-
gest that KGDH ROS generation is the basis of an en-
dogenous autoregulatory mechanism in its own right (at
least in tumor cells). Given KGDH’s pivotal role in the
TCA cycle, it is reasonable to expect diverse mecha-
nisms regulating this enzymatic activity.
Like allosteric regulation, redox regulation can provide
real-time information about bio-availability of a sub-
strate or product, allowing direct modulation of enzym-
atic activity in response. As mentioned above, given the
central role of lipoate acylation and oxidation and reduc-
tion in the KGDH catalytic cycle, it is likely that ratios
of these lipoate intermediates are a rich source of useful
regulatory information, as they are known to be in the
case of PDH (reviewed in [18,19]).
Our data strongly suggest the hypothesis that CPI-613
(a lipoate analog) ‘misinforms’ a lipoate-state-responsive
redox regulatory process controlling KGDH in such a
fashion as to drive increased production of ROS cata-
lyzed by the E3 subunit. The consequences of this misin-
formation include the ROS-induced glutathionylation of
KGDH E2 and down-modulation of KGDH activity
(Figure 6F). In this autoregulation hypothesis, the absence
of CPI-613 (that is, under physiological conditions) would
result in steady-state KGDH ROS production that would
feedback to reversibly inhibit KGDH activity (through
redox modification of KGDH lipoates and possibly other
sulfhydryls) in response to excess reducing potential pro-
duction, down-regulating flux to a set point defined by the
kinetic properties of the circuit, thereby acting as a continu-
ous governor of carbon flow through KGDH.
In our working hypothesis, this feedback modulation
of ROS production is stimulated by the presence of the
non-redox-active CPI-613 analog. For example, ROS
production by E3 can reasonably be expected to be allo-
sterically responsive to the acylation and/or redox status
of neighboring E2 lipoates (consistent with drug effectson purified KGDH; Figure 4A), constituting a target for
the action of lipoate analogs. Such drug modulation of
redox autoregulation is a plausible detailed mechanism
for the contribution of KGDH inhibition to the acute
tumor mitochondrial metabolic collapse observed within
the first hour of treatment, ultimately resulting in com-
mitment to cell death [18]. If CPI-613 is removed by
washout within 3 hours, cells recover and survive [18],
despite the large amounts of mitochondrial ROS pro-
duced during initial exposure to the drug. This is the
expected behavior if an evolved function of this ROS
production includes metabolic regulation rather than
immediate induction of cell death.
The tumor specificity of CPI-613 redox effects sug-
gests that components of the KGDH redox regulatory
process itself (or its immediate context) are altered in
some way(s) in tumor cells. Together with the recent
discovery of direct redox effects on cytosolic glycolytic
flux via cysteine oxidation in the tumor-specific pyruvate
kinase M2 isoform [8], these observations corroborate
the emerging view that the altered redox regulatory state
of cancer metabolism might comprise a useful set of
targets for chemotherapy. Owing to its simultaneous
tumor-specific targeting of a second gate-keeping en-
zyme (PDH) in a mechanistically distinct fashion, CPI-
613 targeting of KGDH may hold particular promise in
this cancer redox-matter/energy metabolism niche. By
targeting two tumor-specific activities, CPI-613 appar-
ently behaves as a treatment ‘cocktail of one.’ It will be
of considerable interest to explore the molecular deter-
minants of these apparent KGDH regulatory alterations
in more detail in the future.
Finally, the mitochondrial redox signal induced by
CPI-613 is quite powerful, as evidenced by the extent of
Prx3 oxidation. Thus, it will be of great interest to ex-
plore possible ROS targets beyond KGDH. Of particular
interest will be the other lipoate-using, E3-containing
mitochondrial complexes (PDH; branched chain alpha-
keto acid dehydrogenase; and the glycine cleavage sys-
tem). For example, while our earlier results demonstrate
that tumor-specific kinase (PDK) regulation of PDH is a
primary proximate target for CPI-613 action on this en-
zyme [18], it remains possible that redox regulation
might play a secondary role in drug effects on PDH.
Conclusions
CPI-613 induces redox-mediated inactivation of the piv-
otal TCA cycle enzyme, KGDH, selectively in tumor
cells. This inhibition of an enzyme vital to energy flow is
associated with the catastrophic inhibition of tumor
mitochondrial metabolism by this drug, followed by
tumor cell death. The CPI-613-induced inactivation is
associated with redox modification of the endogenous
KGDH lipoates of the E2 subunit, apparently in response
Stuart et al. Cancer & Metabolism 2014, 2:4 Page 14 of 15
http://www.cancerandmetabolism.com/content/2/1/4to KGDH E3-generated ROS. This novel mechanism of
action indicates a previously unsuspected reprograming
of KGDH regulation in tumor cells, including redox
autoregulation. These insights add strong impetus to the
newly emerging insight that targeting the altered redox
regulation of matter/energy metabolism in tumor cells
may be an especially attractive source of chemothera-
peutic targets. Moreover, we have previously reported
that CPI-613 simultaneously attacks the other major
entry point for carbon into the typical tumor mitochon-
drial TCA cycle, the lipoate-using enzyme, PDH, using a
distinct, non-redox mechanism. Collectively these results
indicate that CPI-613 simultaneously attacks at least two
cancer metabolic targets, independently, a unique feature
that indicates the possibility of strong clinical potential and
a new opportunity to target cancer by attacking metabolic
regulation [41].
Additional files
Additional file 1: Supplemental Methods.
Additional file 2: Figure S1. In contrast to CPI-613, rotenone-induced
ROS is substantially attenuated in ρ° cells. ROS production was measure
by FACS analysis of DHE fluorescence as in Figure 3 in the main text.
Note that ρ° cells display substantially reduced fluorescence induced by
rotenone (50 μM, 3 hours), while the CPI-613-induced fluorescence is not
attenuated in ρ° cells.
Additional file 3: Figure S2. CPI-613 and CPI-157 have no effect on the
Amplex Red assay system in the absence of KGDH. Shown are results of
the Amplex Red fluorescence assay system (Figure 4A) in the absence of
the KGDH enzyme. Note that neither of the drugs used in these studies
produce significant elevation in the low fluorescence levels produced in
the absence of enzyme.
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